Management and Outcomes of Idiopathic Central Precocious Puberty in Girls
DOI:
https://doi.org/10.12974/2311-8687.2020.08.3Keywords:
Puberty, Precocious puberty, Pubertal progression, Early puberty, Gonadotropin-releasing hormone (GnRH), GnRH agonists, GnRHa histrelin.Abstract
The sequelae of early development are not merely transient but are predictive of difficulties and challenges that persist into adulthood. In fact, the diagnosis and appropriate treatment of early puberty is essential in order to avoid permanent auxological and emotional consequences. GnRH analogues are the treatment of choice for central precocious puberty (CPP), whose main objective is to recover the height potential that is compromised by the premature fusion of growth cartilages. Several active principles and formulations are available. Depot formulations are generally preferred because of better patient compliance; GnRH-a is generally safe and well tolerated. Drug choice depends on the physician’s experience, patient needs, and government regulations of drug prescription.
The aim of this review is to examine the treatment of Idiopathic Central CPP taking in account clinical practice and international literature.
References
Nathan BM, Palmert MR. Regulation and disorders of pubertal timing. Endocrinology and Metabolism Clinics of North America 2005; 34: 617-641. https://doi.org/10.1016/j.ecl.2005.04.015 DOI: https://doi.org/10.1016/j.ecl.2005.04.015
Ritte R, Lukanova A, Tjønneland A, et al. Height, age at menarche and risk of hormone receptor-positive and - negative breast cancer: A cohort study. Int J Cancer 2013; 132: 2619-2629. https://doi.org/10.1002/ijc.27913 DOI: https://doi.org/10.1002/ijc.27913
Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Pediatr Drugs 2015; 17: 273-281. https://doi.org/10.1007/s40272-015-0130-8 DOI: https://doi.org/10.1007/s40272-015-0130-8
Kaplowitz PB, Backeljauw PF, Allen DB. Toward More Targeted and Cost-Effective Gonadotropin-Releasing Hormone Analog Treatment in Girls with Central Precocious Puberty. Hormone Research in Paediatrics 2018; 90: 1-7. https://doi.org/10.1159/000491103 DOI: https://doi.org/10.1159/000491103
Carel JC, Lahlou N, Roger M, et al. Precocious puberty and statural growth. DOI: 10.1093/humupd/dmh012. https://doi.org/10.1093/humupd/dmh012 DOI: https://doi.org/10.1093/humupd/dmh012
Bar A, Linder B, Sobel EH, et al. Bayley-Pinneau method of height prediction in girls with central precocious puberty: Correlation with adult height. J Pediatr 1995; 126: 955-958. https://doi.org/10.1016/S0022-3476(95)70221-0 DOI: https://doi.org/10.1016/S0022-3476(95)70221-0
Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. Journal of Clinical Endocrinology and Metabolism 2004; 89: 3644-3650. https://doi.org/10.1210/jc.2003-031532 DOI: https://doi.org/10.1210/jc.2003-031532
Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. In: Pediatrics. Pediatrics. Epub ahead of print April 2009. DOI: 10.1542/peds.2008-1783. https://doi.org/10.1542/peds.2008-1783 DOI: https://doi.org/10.1542/peds.2008-1783
Oerter Klein K. Precocious Puberty: Who Has It? Who Should Be Treated? J Clin Endocrinol Metab 1999; 84: 411- 414. https://doi.org/10.1210/jcem.84.2.5533 DOI: https://doi.org/10.1210/jcem.84.2.5533
Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 2008; 86: 808-815. https://doi.org/10.1111/j.1651-2227.1997.tb08602.x DOI: https://doi.org/10.1111/j.1651-2227.1997.tb08602.x
Marti-Henneberg C, Vizmanos B. The duration of puberty in girls is related to the timing of its onset. J Pediatr 1997; 131: 618-621. https://doi.org/10.1016/S0022-3476(97)70073-8 DOI: https://doi.org/10.1016/S0022-3476(97)70073-8
Carel JC, Roger M, Ispas S, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999; 84: 1973-1978. https://doi.org/10.1210/jcem.84.6.5647 DOI: https://doi.org/10.1210/jcem.84.6.5647
Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007; 92: 3483-3489. https://doi.org/10.1210/jc.2007-0321 DOI: https://doi.org/10.1210/jc.2007-0321
Heger S, Sippell WG, Partsch C-J. Gonadotropin-Releasing Hormone Analogue Treatment for Precocious Puberty. In: Abnormalities in Puberty. KARGER, pp. 94-125. https://doi.org/10.1159/000084097 DOI: https://doi.org/10.1159/000084097
Genazzani AD, Massolo F, Ferrari E, et al. Long-term GnRHagonist administration revealed a GnRH-independent mechanism stimulating FSH discharge in humans. Eur J Endocrinol 1996; 134: 77-83. https://doi.org/10.1530/eje.0.1340077 DOI: https://doi.org/10.1530/eje.0.1340077
Vatopoulou A, Roos E, Daniilidis A, et al. Long-term effects of treatment of central precocious puberty with gonadotropinreleasing hormone analogs every three months. Gynecol Endocrinol 2020; 1-3. https://doi.org/10.1080/09513590.2020.1770723 DOI: https://doi.org/10.1080/09513590.2020.1770723
Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab 2016; 29: 1241-1248. https://doi.org/10.1515/jpem-2015-0376 DOI: https://doi.org/10.1515/jpem-2015-0376
Silverman LA, Neely EK, Kletter GB, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: A final report of a phase 3 multicenter trial. J Clin Endocrinol Metab 2015; 100: 2354-2363. https://doi.org/10.1210/jc.2014-3031 DOI: https://doi.org/10.1210/jc.2014-3031
Pucarelli I, Segni M, Ortore M, et al. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: A further contribution. J Pediatr Endocrinol Metab 2003; 16: 1005-1010. https://doi.org/10.1515/JPEM.2003.16.7.1005 DOI: https://doi.org/10.1515/JPEM.2003.16.7.1005
Menon PSN. Precocious Puberty, GnRH Stimulation Test and Monitoring GnRH Analog Therapy. Indian Journal of Pediatrics 2015; 82: 980-982. https://doi.org/10.1007/s12098-015-1903-3 DOI: https://doi.org/10.1007/s12098-015-1903-3
Lahlou N, Carel JC, Chaussain JL, et al. Pharmacokinetics and pharmacodynamics of GnRH agonists: Clinical implications in pediatrics. In: Journal of Pediatric Endocrinology and Metabolism. Freund Publishing House Ltd, pp. 723-737.
Lee DS, Ryoo NY, Lee SH, et al. Basal luteinizing hormone and follicular stimulating hormone: is it sufficient for the diagnosis of precocious puberty in girls? Ann Pediatr Endocrinol Metab 2013; 18: 196. https://doi.org/10.6065/apem.2013.18.4.196 DOI: https://doi.org/10.6065/apem.2013.18.4.196
Nebesio TD, Eugster EA. Current Concepts in Normal and Abnormal Puberty. Curr Probl Pediatr Adolesc Health Care 2007; 37: 50-72. https://doi.org/10.1016/j.cppeds.2006.10.005 DOI: https://doi.org/10.1016/j.cppeds.2006.10.005
Carel JC, Léger J. Precocious puberty. N Engl J Med 2008; 358: 2366. https://doi.org/10.1056/NEJMcp0800459 DOI: https://doi.org/10.1056/NEJMcp0800459
Buzi, A Pilotta, D Dordoni, A Lomba F. Pelvic ultrasonography in normal girls and in girls with pubertal precocity. Acta Paediatr 1998; 87: 1138-1145. https://doi.org/10.1111/j.1651-2227.1998.tb00921.x DOI: https://doi.org/10.1111/j.1651-2227.1998.tb00921.x
Calcaterra V, Sampaolo P, Klersy C, et al. Utility of breast ultrasonography in the diagnostic work-up of precocious puberty and proposal of a prognostic index for identifying girls with rapidly progressive central precocious puberty. Ultrasound Obstet Gynecol 2009; 33: 85-91. https://doi.org/10.1002/uog.6271 DOI: https://doi.org/10.1002/uog.6271
de Vries L, Horev G, Schwartz M, et al. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol 2006; 154: 891-898. https://doi.org/10.1530/eje.1.02151 DOI: https://doi.org/10.1530/eje.1.02151
Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin- dependent precocious puberty treated with depot gonadotropinreleasing hormone analogs. J Clin Endocrinol Metab 2008; 93: 2662-2669. https://doi.org/10.1210/jc.2007-2183 DOI: https://doi.org/10.1210/jc.2007-2183
Lazar L, Kauli R, Pertzelan A, et al. Gonadotropinsuppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002; 87: 2090-2094. https://doi.org/10.1210/jcem.87.5.8481 DOI: https://doi.org/10.1210/jcem.87.5.8481
Franceschi R, Gaudino R, Marcolongo A, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril; 93. Epub ahead of print 2010. https://doi.org/10.1016/j.fertnstert.2008.11.016 DOI: https://doi.org/10.1016/j.fertnstert.2008.11.016
Universités P, Paris U, Sorbonne D, et al. Jean-Louis Adrien Thèmes de recherche Recherches en cours Principales publications. Int J Pediatr Endocrinol 1987; 2010: 2-4.
Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93: 190-195. https://doi.org/10.1210/jc.2007-1216 DOI: https://doi.org/10.1210/jc.2007-1216
Lakshman R, Forouhi NG, Sharp SJ, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009; 94: 4953-4960. https://doi.org/10.1210/jc.2009-1789 DOI: https://doi.org/10.1210/jc.2009-1789
Thornton P, Silverman LA, Geffner ME, et al. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev 2014; 11: 306-317.
